Novo Nordisk defends disappointing next-gen obesity drug: 'It will be an important product'
Novo Nordisk defended disappointing trial results for its obesity drug candidate CagriSema, emphasizing its importance as a weight loss treatment ...
Novo Nordisk defended disappointing trial results for its obesity drug candidate CagriSema, emphasizing its importance as a weight loss treatment ...
Danish drugmaker Novo Nordisk showcased flags featuring the logos of their popular diabetes and weight-loss treatments Ozempic and Wegovy during ...
Novo Nordisk's hopes of revolutionizing obesity treatment with its CagriSema drug have been cast into doubt following disappointing trial results, ...
Roche has agreed to a $5.3 billion deal with Zealand Pharma to develop the obesity drug candidate petrelintide, including a ...
The U.S. health regulator has issued a warning letter to Jagsonpal Pharmaceuticals for significant manufacturing lapses at its Rajasthan-based active ...
Shares of Novo Nordisk rose 4.5% after reporting a better-than-expected net profit in the fourth quarter, driven by strong demand ...
Swiss pharmaceutical company Novartis reported better-than-expected sales in Q4, with net sales rising 16% to $13.2 billion, exceeding analyst estimates. ...
Pharmaceutical companies are optimistic about growth under the Trump administration, with hopes for a pro-business approach focusing on cracking down ...
Shares of Novo Nordisk surged 10% following positive early-stage results for its once weekly amycretin obesity drug, which led to ...
Shares of Novo Nordisk dropped over 24% after disappointing results in a trial for its CagriSema weight loss drug, which ...
Copyright © 2026 News Wave
News Wave is not responsible for the content of external sites.